Form 4: Enliven Therapeutics' Chief Medical Officer Acquires 171,000 Stock Options

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025, according to a Form 4 filing.

Summary

• Helen Louise Collins, the Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 indicating a transaction involving derivative securities.
• On February 6, 2025, Collins acquired 171,000 stock options with an exercise price of $22.47.
• These options vest over time, with 1/4th vesting on February 6, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service.
• Following the reported transaction, Collins directly owns 171,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the Chief Medical Officer to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for a Chief Medical Officer role in a company of Enliven Therapeutics' size and stage.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Form 4, Stock Options, Enliven Therapeutics, ELVN, Chief Medical Officer, Helen Louise Collins, Beneficial Ownership, Derivative Securities